Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.
Ian D. Davis(Austin Health), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Ajjai Alva(Michigan Medicine), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), Sandhya Srinivas(Stanford Medicine), Wanling Xie(Dana-Farber Cancer Institute), Jennifer J. Knox(National Cancer Center), D. Scott Ernst, Lori Wood(Dalhousie University), Carmel Pezaro(Royal Marsden NHS Foundation Trust), Takeshi Yuasa(Japanese Foundation For Cancer Research), Allan J. Pantuck(University of California System), Neeraj Agarwal(University of Utah), Sadia Saleem(The University of Texas Southwestern Medical Center)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k